908 Devices (NASDAQ:MASS) Receives “Sell (E+)” Rating from Weiss Ratings

Weiss Ratings reaffirmed their sell (e+) rating on shares of 908 Devices (NASDAQ:MASS) in a report published on Saturday,Weiss Ratings reports.

MASS has been the topic of a number of other reports. Leerink Partnrs lowered 908 Devices from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 13th. Stephens reaffirmed an “overweight” rating and set a $6.00 price objective on shares of 908 Devices in a research note on Wednesday, January 15th. Leerink Partners reaffirmed a “market perform” rating and set a $4.00 price objective (down previously from $12.00) on shares of 908 Devices in a research note on Wednesday, November 13th. Finally, Stifel Nicolaus dropped their price objective on 908 Devices from $17.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th. Two analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $5.33.

908 Devices Price Performance

NASDAQ MASS opened at $2.29 on Friday. The firm has a market cap of $79.74 million, a PE ratio of -1.29 and a beta of 0.96. 908 Devices has a one year low of $1.81 and a one year high of $7.91. The stock’s 50 day simple moving average is $2.36 and its 200 day simple moving average is $3.29.

Institutional Trading of 908 Devices

Hedge funds and other institutional investors have recently modified their holdings of the company. Charles Schwab Investment Management Inc. raised its stake in shares of 908 Devices by 14.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 220,477 shares of the company’s stock valued at $765,000 after purchasing an additional 28,015 shares during the period. Geode Capital Management LLC raised its stake in shares of 908 Devices by 1.2% in the 3rd quarter. Geode Capital Management LLC now owns 567,788 shares of the company’s stock valued at $1,970,000 after purchasing an additional 6,634 shares during the period. Millennium Management LLC raised its stake in shares of 908 Devices by 35.5% in the 2nd quarter. Millennium Management LLC now owns 618,310 shares of the company’s stock valued at $3,184,000 after purchasing an additional 161,922 shares during the period. State Street Corp raised its stake in shares of 908 Devices by 1.2% in the 3rd quarter. State Street Corp now owns 479,044 shares of the company’s stock valued at $1,662,000 after purchasing an additional 5,704 shares during the period. Finally, Barclays PLC raised its stake in shares of 908 Devices by 452.7% in the 3rd quarter. Barclays PLC now owns 46,214 shares of the company’s stock valued at $160,000 after purchasing an additional 37,853 shares during the period. Institutional investors and hedge funds own 88.06% of the company’s stock.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.